Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Phase 2

Terminated

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 10

Registration Number: NCT00041288

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States

and more 20 locations

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 175

Registration Number: NCT00030719

Locations: 🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 28 locations

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 22

Registration Number: NCT00003727

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-05

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 24

Registration Number: NCT00003194

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2017-07-11

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00047281

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Phase 2

Completed

Conditions: Brain Tumor
Central Nervous System Tumor

Interventions: Biological: Sargramostim
Drug: cyclophosphamide
Drug: melphalan
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 31

Registration Number: NCT00002594

Locations: 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸
Miami Children's Hospital, Miami, Florida, United States

and more 114 locations

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Ovarian Cancer
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 11

Registration Number: NCT00002943

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Cytarabine
Biological: Filgrastim
Drug: Dexamethasone
Radiation: Involved-Field Radiation Therapy
Drug: Prednisone
Drug: Vincristine Sulfate Liposome

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-12

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1734

Registration Number: NCT00025259

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 172 locations

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: dactinomycin
Biological: filgrastim
Drug: cyclophosphamide
Drug: carboplatin
Drug: doxorubicin hydrochloride
Procedure: conventional surgery
Drug: etoposide
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 203

Registration Number: NCT00002610

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Floating Hospital for Children, Boston, Massachusetts, United States

and more 231 locations

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 475

Registration Number: NCT00004179

Locations: 🇳🇱
Amphia Ziekenhuis - locatie Molengracht, Breda, Netherlands
🇳🇱
Reinier de Graaf Group - Delft, Delft, Netherlands
🇿🇦
Sandton Oncology Centre, Johannesburg, South Africa

and more 256 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy